-
ASH 2024 | Dr. Zhitao Ying: Real-World Data and Implications of CD19 CAR-T Therapy for r/r DLBCL
Study title： Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted by EBMT” (Abstract 607) Dr. Zhitao…
-
ASH 2024 | Dr. Huanling Zhu on Key Advances in Chronic Myeloid Leukemia (CML): Innovations in Therapy and Biomarker Exploration for Treatment-Free Remission
Six Key Advances in CML Research First-Line Asciminib Shows Long-Term Efficacy One of the most significant updates at ASH 2024 was the 96-week data on asciminib as a first-line therapy,…
-
ASH 2024 | Dr. Fengkui Zhang and Dr. Bing Han Latest Advances in the First-in-Class Bifunctional C5 Antibody/Factor H Fusion Protein for PNH Treatment
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, where leading experts in hematology gathered to discuss the…
-
SABCS 2024: Year in Review – Shifting Paradigms in Early Breast Cancer Treatment
At SABCS 2024, Dr. Janice Tsang explored key developments in early breast cancer (EBC) treatment, highlighting the transition from conventional approaches to more personalized, biomarker-driven strategies. The discussion addressed de-escalation of radiotherapy, long-term updates on adjuvant therapies, and the expanding role of immunotherapy (IO) in triple-negative breast cancer (TNBC) and high-risk HR+/HER2- disease.
-
SABCS 2024: Insights on Anthracyclines in High-Risk HR+/HER2- Breast Cancer
At SABCS 2024, Nan Chen, MD, presented insights from a post-hoc analysis of TAILORx, exploring the role of anthracyclines in high genomic risk, node-negative HR+/HER2- breast cancer. The discussion focused on how Recurrence Score (RS) > 31 may influence treatment decisions and the potential impact of tumor size on chemotherapy benefits. These insights challenge prior…
-
OlympiA Trial 10-Year Update: Major Findings from SABCS 2024
At SABCS 2024, Dr. Judy Garber presented the latest 10-year follow-up results from the OlympiA trial, which continue to reinforce the role of adjuvant olaparib in patients with germline BRCA1/2 mutation-associated, high-risk HER2-negative breast cancer. With a median follow-up of 6.1 years (maximum 9.6 years), the trial confirms the long-term benefits of olaparib in reducing…
-
Targeting SUMOylation in Cholangiocarcinoma: A Potential Therapeutic Approach
A recent study published in Hepatology explores the role of SUMOylation in cholangiocarcinoma (CCA) and its potential as a therapeutic target. The research analyzed tumors from multiple patient cohorts and…
-
ESMO 2024丨Early Immunotherapy Significantly Extends Overall Survival in Triple-Negative Breast Cancer Patients
The final results of the KEYNOTE-522 trial confirm the potential of pembrolizumab to change patient management, though careful patient selection and toxicity monitoring are essential.
Connecting Medical Expertise through Media